The influence of renin angiotensin aldosterone system blockers on asymmetric dimethylarginine levels in patients with chronic glomerulonephritis

1. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol., 23,168-175, 2003.10.1161/01.ATV.0000051384.43104.FCSearch in Google Scholar

2. Böger R.H. et al. Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction, Its Role in Hypercholesterolemia. Circulation, 98, 1842-1847, 1998.10.1161/01.CIR.98.18.1842Search in Google Scholar

3. Caglar K. et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int., 70, 781-787, 2006.10.1038/sj.ki.5001632Search in Google Scholar

4. Colonna De Gennaro V. et al. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med Sci Monit., 15, RA91-101, 2009.Search in Google Scholar

5. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia, 32, 219-226, 1989.10.1007/BF00285287Search in Google Scholar

6. Fliser D. et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol., 16, 2456-2461, 2005.10.1681/ASN.2005020179Search in Google Scholar

7. Fujii H. et al. Renin-Angiotensin System Inhibitors Reduce Serum Asymmetric Dimethylarginin Levels and Oxidative Stress in Normotensive Patients with Chronic Kidney Disease. Nephron Extra, 4, 18-25, 2014.10.1159/000358886Search in Google Scholar

8. Fujimi-Hayashida A. et a l. Association of asymmetric dimethylarginine with severity of kidney injury and decline in kidney function in IgA nephropathy. Am J Nephrol., 33,1-6,2011.10.1159/000322367Search in Google Scholar

9. Hibbs J.B., Vavrin Z., Taintor R.R. L-Arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol.,138: 550-565,1987.Search in Google Scholar

10. Makino H. et al. INNOVATION Study Group: Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care, 30, 1577-1578, 2007.10.2337/dc06-1998Search in Google Scholar

11. Paisley K.E. et al. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int., 63, 624-633, 2003.10.1046/j.1523-1755.2003.00768.xSearch in Google Scholar

12. Ruggenenti P. et al. Reno-protective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet, 354, 359-364, 1999.10.1016/S0140-6736(98)10363-XSearch in Google Scholar

13. Stehouwer C.D. et al. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction – the Hoorn Study. Kidney Int., 92, S42-S44, 2004.10.1111/j.1523-1755.2004.09211.x15485416Search in Google Scholar

14. Webb N.J. et al. Randomized, double-blind, controlled study of losartan in children with proteinuria. Clin J Am Soc Nephrol., 5, 417-424, 2010.10.2215/CJN.06620909282756920089489Search in Google Scholar

15. Zoccali C., Kielstein J.T. Asymetric dimethylarginine: A new player in the pathogenesis of renal disease? Curr Opin Nephrol Hypertens, 15, 314-320, 2006.10.1097/01.mnh.0000222701.22583.e816609301Search in Google Scholar